ARGUS International

Our Services

AKI Detection

EFFLUX is a point-of-care acute kidney injury (AKI) monitoring device for hospital, medical, surgical and ICU patients. EFFLUX is the first in class point-of-care AKI detection device, which is revolutionizing the way ICU patients are treated, monitored and diagnosed. It is compact, lightweight, adjusts to fit any hospital bed, and comes with a user-friendly interface. 

No Lengthy Waits for Lab Results

EFFLUX not only provides requisite early detection, it also provides on-going patient monitoring without the need to send numerous samples to the laboratory and having to wait for the results. This is made possible due to the nature of the device with real-time, point-of-care monitoring of numerous biomarkers. This provides physicians with the data stream necessary to manage patients that have quickly deteriorating kidney function complicated by the treatments being administered.

Hands On Integration

EFFLUX  drastically changes the landscape, enabling healthcare providers to obtain critical data points  from urine flow at their fingertips, that are both real-time and relevant to determining a patient's risk for AKI; results they are unable to achieve from current lab tests. Present-day systems involve arduous, time consuming, and laborious processes. The introduction of EFFLUX  effectively makes these outdated procedures obsolete.

About Us

Why Our Devices

With a team with over a half century combined experience stemming from the largest medical device companies in the world, ARGUS International prides itself in excellence and ground breaking innovation. You can rest assured that our products will stand the test of time.

How We Help

At ARGUS, we developed a life saving devices that help detect, monitor and alert physicians of patient impending risk of hospital acquired Acute Kidney Injury (AKI) and other conditions that are both common and costly issues for patients in hospital ICU's and post-operative environments. Our aim is save patients from End Stage Renal Disease (ESRD), lower hospital readmission and optimize patient outcome. 


Experience the Difference

The ARGUS difference - state-of-the-art AKI detection and monitoring - EFFLUX ™.  Accuracy you need in a point of care device.  Information at your fingertips where it should be; not in a lab. 

Leadership Team

C. Rafael Ortiz

Chief Executive Officer & Chairman

Biomedical Engineer, Founder

Fmr. Secretary SFB and BMES Memphis Chapter

US Army Veteran, Sr. Research & Development Engineer


Find out more

Chris Lyle

Chief Operations Officer

MBA Operations Management 

3PL & 4PL Sourcing, Six Sigma, Manufacturing Processes, 


Dumkele Anifowoshe

Chief Financial Officer

BS. Applied Physics, Certified Public Accountant

Tax Consultant KPMG, State of Tennessee Auditor, Partner Advantage CPA Group LLC.

Find out more

Clinical Trials

The University of Michigan has partnered with ARGUS International to perform the first EFFLUX clinical efficacy trials (Ongoing Now!).

Subscribe

Sign up to hear from us.

Upcoming Events

We are exhibiting at 

2018 HIMSS 


Sands Expo Center
Las Vegas, NV
March 5-9, 2018

Booth 9900-105


Register Now

We are exhibiting at 

AKI & CRRT 2018


Manchester Grand Hyatt   
San Diego, CA
March 6-9, 2018

Booth # 14

Contact Us

Drop us a line!

ARGUS International

3121 Bartlett Corporate Drive, Suite 102, Bartlett, Tennessee 38133, United States

(901) 842-1871

Hours

Saturday/Sunday: Closed